Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sagent Turns Generic Injectable Shortages Into Business Opportunity

This article was originally published in PharmAsia News

Executive Summary

The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.

Advertisement

Related Content

Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
GDUFA’s Perfect Storm: Approvals Drop, Submissions Jump
Generic Rx Shortage Initiative Stuck: Too Few Manufacturers To Pick Up Slack
Generic Injectables: Pharma Takes A Shot At A Growing Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC087437

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel